Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366979 | 0.88 | RXFP1 (0.80) | RXFP1 | |
| SCHEMBL16323913 | 0.88 | ALDH1A1 (0.81) | PKMALDH1A1HTTSMN1; SMN2TSHR | |
| SCHEMBL13942736 | 0.85 | MEN1 (0.57) | PKM | |
| SCHEMBL16322837 | 0.84 | ADORA2B (0.76) | KDM4ETDP1 | |
| SCHEMBL3397866 | 0.84 | PKM (0.80) | PKMALDH1A1HTTSMN1; SMN2TSHR | |
| SCHEMBL3395610 | 0.84 | KIF11 (0.75) | ALDH1A1SMN1; SMN2TSHRGAA | |
| SCHEMBL19752619 | 0.84 | KIF11 (0.75) | ALDH1A1SMN1; SMN2TSHRGAA | |
| SCHEMBL10113026 | 0.82 | DHFR (0.62) | PKMALDH1A1HTTSMN1; SMN2TSHR | |
| SCHEMBL10113186 | 0.82 | ALDH1A1 (0.72) | PKMALDH1A1HTTSMN1; SMN2TSHR | |
| SCHEMBL3941131 | 0.82 | MEN1 (0.52) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175556-A1 | DIHYDROPYRIMIDIN-2(1H)-ONES AND DIHYDROPYRIMIDIN-2(1H)-THIONES AS INHIBITORS OF SODIUM IODIDE SYMPORTER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2682389-A1 | Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175556-A1 | DIHYDROPYRIMIDIN-2(1H)-ONES AND DIHYDROPYRIMIDIN-2(1H)-THIONES AS INHIBITORS OF SODIUM IODIDE SYMPORTER | SLC40A1, SLC5A11, SLC20A1 | PKM 2941/4885ALDH1A1 583/4885HTT 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.